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ABSTRACT 
Background: In colorectal cancer (CRC), inflammatory responses have been reported to 
associate with patient survival. However, the specific signalling pathways responsible for 
regulating inflammatory responses are not clear. Src family kinases (SFKs) impact 
tumourigenic processes, including inflammation.  
 
Methods: The relationship between SFK expression, inflammatory responses and cancer 
specific survival (CSS) in stage I-III CRC patients was assessed using immunohistochemistry 
on a 272 patient discovery cohort and an extended 822 patient validation cohort. 
 
Results: In the discovery cohort, cytoplasmic FGR associated with improved CSS (P=0.019), 
with membrane HCK (p=0.093) trending towards poorer CSS. In the validation cohort 
membrane FGR (p=0.016), membrane HCK (p=0.019), and cytoplasmic HCK (p=0.030) all 
associated with poorer CSS. Both markers also associated with decreased proliferation and 
cytotoxic T-lymphocytes (all p<0.05).  Furthermore, cytoplasmic HCK was an independent 
prognostic marker compared to common clinical factors. To assess synergy a combine 
FGR+HCK score was assessed. The membrane FGR+HCK score strengthened associations 
with poor prognosis (p=0.006), decreased proliferation (p<0.001) and cytotoxic T-
lymphocytes (p<0.001) 
 
Conclusions: SFKs associate with prognosis and the local inflammatory response in patients 
with stage I-III CRC. Active membrane FGR and HCK work in parallel to promote tumour 
progression and down-regulation of the local inflammatory lymphocytic response. 
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INTRODUCTION 
Colorectal cancer (CRC) is the second most common cause of cancer death in Europe1.  
Although outcomes have improved over the past decades, predominantly as a result of 
improvements in surgical technique and adjuvant/neo-adjuvant therapies, survival still 
remains poor, with 5-year survival of 60% across all stages of disease2.  It is clear that the 
present TNM-based staging of CRC is suboptimal, with a need to identify characteristics 
pertaining to both the tumour and the host which may not only guide prognosis, but also 
novel adjuvant therapies.    
Local and systemic inflammatory responses have been widely demonstrated to play an active 
role in tumour development across a wide range of cancers including CRC3-5.  This is now an 
area of intense research producing inflammatory-based scoring systems such as the Galon’s 
immunoscore6,  Klintrup-Makinen grade7 or Glasgow Microenvironment score (GMS)8 for 
local inflammation and for systemic inflammation the modified Glasgow prognostic score 
(mGPS)9-11 or neutrophil-lymphocyte ratio (NLR)12.   Of note all of these local and systemic 
inflammatory scoring algorithms have prognostic value independent of TNM staging13.  
However, the signalling pathways driving these local and systemic inflammatory responses in 
CRC are not clear. A better understanding of the mechanisms underlying the link between the 
tumour and inflammation by identifying key signalling pathways and their prognostic value 
may provide novel therapeutic targets for CRC. 
One plausible candidate is the Src family kinases (SFKs).  Deregulation of SFK activation is 
found in many cancers such as pancreatic, breast, ovarian, prostate, renal and CRC14-19. SFKs 
are known to regulate inflammatory responses and have a role in promoting metastasis.  In 
CRC, SFK expression is increased in 80% of CRC as compared with normal colonic 
epithelium and has been shown to correlate with an increase in CRC metastases19, 20. 
Furthermore, expression of SFKs on myeloid cells is associated with poor prognosis and a 
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pro-tumour M2-like macrophage endotype21. However, there is little data regarding 
individual SFK expression within the tumour cells and their impact on patient survival and 
clinical response in CRC.    
SFKs comprise eight members expressed in mammalian cells (Src kinase, BLK, FGR, FYN 
YES, HCK, LCK & LYN). All SFKs reside in an inactive state until dephosphorylated at 
Y527, and in turn auto-phosphorylated at Y419, following which phosphorylate their 
downstream targets such as focal adhesion kinase (FAK). As this mechanism is common to 
all family members, antibodies that recognise Y419 alone cannot be employed to determine 
which SFK is activated in a patient’s tumour. However, cellular location can be employed as 
a surrogate of SFK activation, when inactive family members reside in the cytoplasm and 
once activated they translocate to the membrane, enabling each SFK member to be analysed 
individually.  
The current study aims to assess tumour cell SFK expression at the membrane (active) and 
cytoplasm (inactive) to establish the effect of individual SFK members on survival, 
clinicopathological characteristics and inflammatory responses in patients with CRC.  
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METHODS 
Patients 
Discovery cohort patients were identified from a prospectively collected and maintained 
database of CRC resections performed in a single surgical unit in Glasgow Royal Infirmary. 
271 patients who between 1997 and 2007 had undergone an elective, potentially curative 
resection for stage I-III CRC and were contained within a previously constructed tissue 
microarray (TMA) were included. The discovery cohort was extended to a larger validation 
cohort by the inclusion of retrospectively identified patients from CRC resections performed 
with the Western General Hospital, Glasgow.  The validation cohort contained 937 patients 
who between 2000 and 2007 had undergone an elective, potentially curative resection for 
stage I-III CRC and were contained within previously constructed TMAs.  Resection was 
considered curative on the basis of pre-operative computed tomography and intra-operative 
findings.  Patients who had died within 30 days of surgery were excluded. Ethical approval 
was obtained from the West of Scotland Research Ethics Committee. 
Clinicopathological Characteristics 
Tumours were staged using the fifth edition of the AJCC/UICC-TNM staging system22.  The 
presence of venous invasion was assessed using elastica staining.  Following surgery, patients 
with stage III or high-risk stage II disease and without significant co-morbid disease 
precluding adjuvant treatment were considered for 5-fluorouracil-based chemotherapy.  
Patients were followed up and date and cause of death were crosschecked with the cancer 
registration system and the Registrar General (Scotland).  Cancer-specific survival (CSS) was 
measured from date of surgery until date of death from CRC. 
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The presence of tumour necrosis and tumour stroma percentage (TSP) were assessed as 
previously described23. Mismatch repair (MMR) status was assessed as previously described8. 
Ki67 proliferation index and BRAF status were previously established for both cohorts.  
The local inflammatory cell infiltrate was assessed using the Klintrup-Mäkinen (KM) grade 
as previously described on full sections taken at the deepest point of invasion24.  Tumour 
infiltrating lymphocytes (TILs) were established from patient reports. CD3, CD8 and FoxP3 
cell counts were established using immunohistochemistry on full sections as previously 
described24. Briefly, cell counts were measure separately at the invasive margin, within the 
stroma and within the cancer cell nests using a semi-quantitative method as absent, low, 
moderate or high.  Absent and low were then grouped as low and moderate and high grouped 
as high.  
Serum C-reactive protein (CRP) and albumin were recorded prospectively and measured 
within 30 days prior to surgery. The pre-operative systemic inflammatory response was 
defined using the mGPS.  The mGPS was calculated as previously described13. Neutrophil, 
platelet and lymphocyte counts were previously established in this cohort and used to 
generate the NLR. 
Immunohistochemistry 
Immunohistochemical expression of SFK members and downstream target, FAK861 was 
carried out using a previously constructed CRC TMA (Figure S1)25-27.  Sections were 
dewaxed in histoclear then rehydrated using graded alcohols.  Antigen retrieval was 
performed under pressure for 5 minutes using either citrate buffer pH6 (Src kinase, FAK861, 
FYN, HCK, LCK, YES) or EDTA buffer pH9 (SFK419, LYN, FGR) before cooling for 20 
minutes.  Endogenous peroxidase activity was blocked using 3% hydrogen peroxide for 10 
minutes.  5% normal horse serum was applied for 20 minutes at room temperature as a 
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blocking solution. TMA sections were incubated overnight at 4oC with SFK419 (1:25; 
Millipore), FAK861 (1:200, Invitrogen), FYN (1:1500), LYN (1:25), HCK (1:1000), LCK 
(1:200) and YES (1:150, Cell Signaling) or for 60 minutes at room temperature for Src kinase 
(1:200) and FGR (1:4000, Cell Signaling) before washing the sections in TBS.  Envision 
(Dako) was added to the sections for 30 minutes at room temperature before washing in TBS. 
DAB substrate was added for five minutes until colour developed before washing in running 
water for ten minutes.  Slides were then counterstained in haematoxylin for 60 seconds and 
blued with Scotts’ tap water before being dehydrated through a series of graded alcohols.  
Cover slips were applied using distrene, plasticizer, xylene (DPX).  
Scoring 
Stained TMA sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden 
City, Hertfordshire, UK) at x20 magnification and visualized on SlidePath Digital Image Hub 
(Leica Biosystems, Milton Keynes, UK). Assessment of SFKs and FAK861 expression was 
performed by a single examiner (A.P or S.H) blinded to clinical data at x20 magnification 
(total magnification x400) using the weighted histoscore (H-score)28-30.  The weighted 
histoscore is calculated using the following equation: 0 x (% cells not stained) + 1 x (% cells 
weakly stained) + 2 x (% cells moderately stained) + 3 x (% cells strongly stained).  This 
gives a range of scores from 0 to 300 and is calculated individually for membrane and 
cytoplasmic staining. To ensure reproducibility, 10% of tumours were co-scored by a co-
investigator (J.E or A.K.R).   
Statistical Analysis 
Within the discovery cohort, patient scores were analyzed by ROC analysis to determine the 
appropriate cut-off values for low and high expression (Table S1). These were then verified 
for significant factors using the validation cohort. The relationship between 
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clinicopathological characteristics and protein expression was examined using the chi-square 
test for linear trend.  The relationship between expression and CSS was examined using 
Kaplan-Meier method. The log rank test was utilized to compare significant differences 
between subset groups using univariate analysis. Multivariate cox regression analysis was 
performed to identify those factors that were independently associated with CSS. A P-value 
<0.05 was considered statistically significant.  All analyses were performed using SPSS 
version 22.0 (IBM SPSS) and conformed to the REMARK criteria. 
  
 9 
 
RESULTS 
SFKs and cancer-specific survival in a discovery cohort of 271 patients with CRC 
A total of 271 patients who underwent an elective, potentially curative resection of stage I-III 
CRC (Table S2) were included in the study.  Almost two thirds of patients were 65 or older at 
the time of surgery and just over half were male.  Two thirds of patients underwent resection 
for colon cancer.  Twenty patients (7%) had pathological confirmation of stage I disease, 
whereas 132 (49%) and 120 (44%) patients had stage II and stage III disease respectively.  
Thirty-five patients (13%) had MMR deficient CRC, and ninety-nine patients (36%) showed 
venous invasion. The median follow-up of survivors was 11.3 years (range 6.2-16.2 years) 
with 95 cancer-associated deaths and 68 non-cancer deaths. 
Associations between tumour cell SFK expression and CSS are shown in Table 1. Src kinase, 
FYN, LYN and FAK861 were not associated with CSS at any cellular location. However, 
cytoplasmic FGR was significantly associated with improved CSS (HR 0.54 95% CI 0.31-
0.91, p=0.019). Membrane HCK also trended towards an association with decreased CSS 
(HR 1.46 95%CI 0.93-2.29, p=0.093).   
  Membrane Cytoplasmic 
  N (%) 10yr CSS (SEM) P N (%) 10yr CSS (SEM) P 
SFK419 (n=260)  
  
0.407 
  
0.416 
Low expression 179 (69) 65 (4) 
 
142 (55) 65 (4) 
 
High expression 81 (31) 59 (6) 
 
118 (45) 61 (5) 
 
Src kinase  (n=268) 
  
0.787 
  
0.649 
Low expression 30 (11) 55 (1) 
 
63 (24) 65 (7) 
 
High expression 238 (89) 64 (3) 
 
205 (76) 63 (4) 
 
FGR (n=225) 
 
 
0.855 
 
 
0.019 
Low expression 70 (31) 66 (6) 
 
150 (67) 59 (04) 
 
High expression 155 (69) 63 (4) 75 (33) 75 (5) 
 
FYN (n=244) 
  
0.419 
  
0.598 
Low expression 187 (77) 67 (4) 
 
93 (38) 63 (5) 
 
High expression 56 (23) 56 (8) 
 
151 (62) 64 (4) 
 
HCK (n=232) 
  
0.093 
  
0.393 
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Low expression 112 (48) 71 (5) 
 
87 (38) 68 (5) 
 
High expression 120 (52) 57 (5) 
 
145 (62) 61 (4) 
 
LYN (n=246) 
  
0.196 
  
0.789 
Low expression 190 (77) 61 (4) 
 
176 (72) 63 (4) 
 
High expression 56 (23) 74 (6) 
 
70 (28) 68 (6) 
 
FAK861 (n=252) 
   
  
0.233 
Low expression - - - 218 (87) 66 (3) 
 
High expression       34 (13) 52 (9)   
Table 1.   SFK expression and survival in discovery cohort patients with colorectal cancer (n=272) 
SFKs and cancer-specific survival in a 822 validation cohort of patients with CRC 
As FGR was associated with CSS and a trend was observed for HCK, these were taken 
forward for investigation in the validation cohort along with activation site SFK419. Only 
patients with a valid score for all three SFK members were included in the analysis. A total of 
822 patients who underwent an elective, potentially curative resection of stage I-III CRC 
(Table S2) were included in the study.  Two thirds of patients were 65 or older at the time of 
surgery and just over half were male.  Three quarter of patients underwent resection for colon 
cancer.  114 patients (14%) had pathological confirmation of stage I disease, whereas 396 
(48%) and 312 (38%) patients had stage II and stage III disease respectively. One hundred 
and thirty-eight patients (17%) had MMR deficient CRC, and 268 patients (33%) had venous 
invasion. The median follow-up of survivors was 12.1 years (range 6.2-17.0 years) with 231 
cancer-associated deaths and 270 non-cancer deaths. 
Associations between tumour cell SFK expression and CSS are shown in Table 2. SFK416 did 
not associate with CSS at any cellular location. Similarly, associations between cytoplasmic 
FGR and CSS were not observed.  However, membrane FGR associated with poorer CSS 
(HR 1.38 95% CI 1.06-1.80, p=0.016, Figure 1A).  Similarly, HCK associated with poorer 
CSS at both cellular locations (membrane – HR 1.48 95% CI 1.06-2.06, p=0.019, Figure 1B; 
cytoplasmic – HR 1.34 95% CI 1.03-1.75, p=0.030). 
 Membrane Cytoplasmic 
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 N (%) 10yr CSS (SEM) P N (%) 10yr CSS (SEM) P 
SFK419 
  
0.341 
  
0.941 
Low expression 746 (91) 70 (2) 
 
156 (19) 68 (4) 
 
High expression 69 (9) 64 (6) 
 
652 (81) 70 (2) 
 
FGR 
  
0.016 
  
0.195 
Low expression 368 (45) 74 (2) 
 
228 (29) 65 (3) 
 
High expression 447 (55) 66 (2) 
 
571 (71) 71 (2) 
 
HCK 
  
0.019 
  
0.030 
Low expression 704 (86) 71 (2) 
 
460 (60) 73 (2) 
 
High expression 111 (14) 59 (5) 
 
313 (40) 65 (3) 
 
FGR+HCK 
  
0.006 
  
0.721 
Both low 335 (41) 76 (2) 
 
136 (18) 72 (4) 
 
One high 402 (49) 66 (3) 
 
408 (53) 69 (2) 
 
Both high 78 (10) 60 (6) 
 
225 (29) 69 (3) 
 
Table 2.   SFK expression and survival in validation cohort patients undergoing potentially curative 
resection of colorectal cancer (n=822) 
 
Figure 1.  Activated FGR and HCK associates with poor prognosis in patients undergoing potentially 
curative resection of colorectal cancer (n=822). Kaplan Meier curves showing association of CSS and (A) 
membrane FGR, (B) membrane HCK and (C) combined membrane FGR+HCK in 822 patients with CRC. 
 
HCK and FGR differentially associate with clinicopathological factors and markers of 
inflammation 
Associations between FGR, clinicopathological characteristics and inflammatory markers as 
shown in Table 3. Activated membrane FGR showed significant associations with poor 
prognostic markers including higher TNM-stage (p=0,041), poorer differentiation (p=0.006), 
decreased necrosis (p=0.028), T-lymphocytes (p=0.022), cytotoxic T-lymphocytes (p=0.010) 
and increased mGPS (p=0.013).  However, inactive cytoplasmic FGR significantly associated 
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with increased age (p=0.023), colon cancer (p=0.009), decreased peritoneal involvement 
(p=0.007), increased proliferation rate (p<0.001), deceased TSP (p=0.046), increased T-
lymphocytes (p=0.032), cytotoxic T-lymphocytes (p=0.001) and regulatory T-lymphocytes 
(p=0.001) as well as increased PD-L1 TILs (p=0.019) and decreased PD-L1 tumour 
expression (p=0.013). 
Associations between HCK, clinicopathological characteristics and inflammatory markers are 
shown in Table 3.  Activated membrane HCK showed significant associations with younger 
age (p=0.013), rectal cancer (p=0.002), higher TNM-stage (p=0.014), lower proliferation rate 
(p<0.001), lower mGPS (p=0.014), as well as decreased cytotoxic T-lymphocytes (p<0.001), 
PD1-TILs (p=0.026) and PD-L1 TILs (p=0.032) but higher PD-L1 tumour expression 
(p=0.009). However, inactive cytoplasmic HCK only associated with increased TNM-stage 
(p=0.001), increased margin involvement (p=0.033), decreased MMR deficiency (p=0.038), 
decreased cytotoxic lymphocytes (p=0.015) and increased PD-L1 tumour expression 
(p<0.001). 
 
Membrane FGR Cytoplasmic FGR Membrane HCK Cytoplasmic HCK 
Absent Present P Low High P Low High P Low High P 
(n=368) (n=447)   (n=228) (n=571)   (n=704) (n=111)   (n=460) (n=313)   
Age 
  
0.137 
  
0.023   
 
0.013 
  
0.183 
<65 109 (29) 153 (34)   86 (38) 169 (29)   215 (30) 47 (42)   137 (30) 107 (34) 
 
>65 264 (71) 296 (66)   143 (62) 408 (71)   496 (70) 64 (58)   328 (70) 208 (66) 
 Sex 
  
0.438 
  
0.058   
 
0.408 
  
0.521 
Female 166 (45) 212 (47)   93 (41) 277 (48)   331 (47) 47 (42)   219 (47) 141 (45) 
 Male 207 (55) 237 (53)   136 (59) 300 (52)   380 (53) 64 (58)   256 (53) 174 (55) 
 Tumour site 
  
0.625 
  
0.009   
 
0.002 
  
0.584 
Colon  283 (76) 334 (74)   158 (69) 449 (78)   547 (77) 70 (63) 
  
352 (76) 233 (74) 
 Rectum 90 (24) 115 (26)   71 (31) 128 (22)   164 (23) 41 (37) 
  
113 (24) 82 (26) 
 TNM-stage 
  
0.041 
  
0.369   
 
0.014 
  
0.001 
I 59 (16) 55 (12)   26 (11) 82 (14)   107 (15) 7 (6)   79 (17) 27 (9) 
 II 185 (50) 211 (47)   113 (49) 279 (48)   342 (48) 54 (49)   227 (49) 154 (49) 
 III 129 (34) 183 (41)   90 (39) 216 (37)   262 (37) 50 (45)   159 (34) 134 (42) 
 Differentiation 
  
0.006 
  
0.149   
 
0.219 
  
0.016 
Mod/well 349 (94) 395 (88)   202 (88) 528 (92)   640 (90) 104 (94)   430 (93) 275 (87) 
 Poor 24 (6) 54 (12)   27 (12) 49 (8)   71 (10) 7 (6)   35 (7) 40 (13) 
 Venous invasion 
  
0.954 
  
0.619   
 
0.138 
  
0.830 
Absent 251 (67) 303 (68)   151 (66) 391 (69)   486 (68) 68 (61)   311 (67) 213 (68) 
 Present 122 (33) 146 (32)   78 (34) 186 (32)   225 (32) 43 (39)   154 (33) 102 (32) 
 Margin involvement 
  
0.595 
  
0.942   
 
0.822 
  
0.033 
No 353 (95) 421 (94)   216 (94) 545 (95)   670 (94) 104 (94)   445 (96) 290 (92) 
 Yes 20 (5) 28 (6)   13 (6) 32 (5)   41 (6) 7 (6)   20 (4) 25 (8) 
 Peritoneal involvement 
  
0.976 
  
0.007   
 
0.798 
  
0.746 
No 272 (73) 327 (73)   151 (66) 435 (75)   517 (73) 82 (74)   340 (73) 227 (72) 
 Yes 101 (27) 122 (27)   78 (34) 142 (25)   194 (27) 29 (26)   125 (27) 88 (28) 
 Mismatch repair status   
  
0.510 
  
0.947   
 
0.707 
  
0.038 
Competent 312 (84) 369 (82)   188 (83) 479 (83)   589 (83) 92 (84)   374 (81) 271 (86) 
 Deficient 59 (16) 79 (18)   39 (17) 98 (17)   121 (17) 17 (16)   90 (19) 43 (14) 
 
Proliferation Index 
  
0.358 
  
<0.00
1 
  
 
<0.00
1   0.088 
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Low 164 (44) 213 (48)   142 (63) 222 (38)   298 (42) 79 (73)   199 (43) 154 (49) 
 High 206 (56) 235 (52)   84 (37) 354 (62)   412 (58) 29 (30)   264 (57) 159 (51) 
 Necrosis  
  
0.028 
  
0.706   
 
0.942 
  
0.236 
Low 207 (57) 283 (64)   135 (59) 343 (61)   424 (61) 66 (61)   283 (62) 180 (58) 
 High 158 (43) 157 (36)   92 (41) 220 (39)   272 (39) 43 (39)   171 (38) 130 (42) 
 Tumour stroma percentage 
  
0.069 
  
0.046   
 
0.348 
  
0.126 
Low 290 (80) 321 (74)   153 (72) 448 (79)   539 (77) 72 (73)   355 (78) 221 (73) 
 High 75 (20) 113 (26)   60 (28) 122 (21)   161 (23) 27 (27)   100 (22) 82 (27) 
 Klintrup-Makinen grade 
  
0.569 
  
0.956   
 
0.879 
  
0.448 
Weak 249 (68) 291 (66)   153 (67) 379 (67)   467 (67) 73 (66)   299 (66) 213 (69) 
 Strong 117 (32) 149 (34)   74 (33) 185 (33)   229 (33) 37 (34)   155 (34) 98 (31) 
 CD3+ Lymphocytes 
  
0.022 
  
0.032   
 
0.303 
  
0.765 
Low 101 (30) 165 (40)   93 (43) 172 (33)   224 (35) 42 (38)   151 (35) 107 (36) 
 Moderate 110 (33) 117 (28)   53 (25) 168 (32)   194 (30) 33 (31)   126 (30) 88 (30) 
 High 125 (37) 136 (32)   68 (32) 187 (35)   228 (35) 33 (31)   149 (35) 100 (34) 
 
CD8+ Lymphocytes 
  
0.010 
  
0.001   
 
<0.00
1   0.015 
Low 141 (43) 202 (49)   118 (57) 222 (43)   278 (44) 65 (62)   180 (43) 155 (53) 
 Moderate 82 (25) 117 (28)   47 (22) 146 (28)   176 (28) 23 (22)   117 (28) 65 (22) 
 High 107 (32) 92 (29)   44(21) 153 (29)   184 (29) 17 (16)   124 (29) 71 (24) 
 FoxP3+ Lymphocytes 
  
0.091 
  
0.001   
 
0.263 
  
0.565 
Low 83 (30) 135 (36)   90 (46) 123 (28)   177 (32) 41 (40)   114 (31) 94 (35) 
 Moderate 106 (38) 131 (35)   53 (27) 181 (41)   220 (40) 17 (16)   142 (39) 90 (34) 
 High 91 (32) 106 (29)   53 (27) 141 (32)   151 (28) 46 (44)   111 (30) 82 (31) 
 PD1 – TILs 
  
0.177 
  
0.081   
 
0.026 
  
0.829 
Low 222 (66) 300 (70)   158 (73) 354 (66)   442 (66) 83 (77) 
  
296 (67) 202 (67) 
 High 116 (34) 127 (30)   60 (27) 183 (34)   227 (34) 25 (23) 
  
143 (33) 101 (33) 
 PD-L1 – TILs 
  
0.761 
  
0.019   
 
0.013 
  
0.704 
Low 259 (76) 318 (75)   183 (81) 385 (73)   215 (30) 47 (42)   331 (76) 226 (74) 
 High 82 (24) 106 (25)   43 (19) 143 (27)   496 (70) 64 (58)   107 (24) 78 926) 
 
PD-L1 – tumour 
  
0.262 
  
0.013   
 
0.009 
  
<0.00
1 
Low 194 (57) 231 (53)   108 (48) 306 (57)   380 (57) 51 (44) 
  
261 (60) 141 (46) 
 High 144 (43) 202 (47)   119 (52) 227 (43)   285 (43) 65 (56) 
  
178 (40) 168 (54) 
 
mGPS 
  
0.013 
  
0.789   
 
0.014 194 (55) 
 
0.169 
0 181 (61) 189 (52)   107 (53) 256 (57)   299 (54) 71 (65)   
 
160 (59) 
 1 77 (26) 105 (29)   66 (32) 115 (26)   153 (28) 29 (26)   96 (27) 75 (28) 
 2 40 (13) 70 (19)   30 (15) 78 (17)   100 (18) 10 (9)   65 (18) 38 (14) 
 NLR 
  
0.097 
  
0.131   
 
0.815 
  
0.184 
<5 231 (75) 147 (76)   147 (76) 330 (70)   418 (72) 68 (73)   264 (70) 197 (75) 
 
>5 76 (25) 46 (24)   46 (24) 139 (30)   163 (28) 25 (27)   111 (30) 65 (25)   
Table 3. Relationship between FGR or HCK expression and clinicopathological characteristics in patients 
undergoing potentially curative resection of colorectal cancer (n=822). 
Activated membrane FGR and HCK work in parallel to promote tumour progression 
and dampen lymphocytic infiltration 
As FGR and HCK show similar associations with prognosis and lymphocytic infiltration, 
they were combined into a single score to assess if they work together or synergistically. FGR 
and HCK were combined as follows at both cellular locations: low FGR and low HCK = both 
low; low FGR or high HCK = one high; high FGR and high HCK = both high. When 
assessed for associations with CSS, a high membrane FGR+HCK score significantly 
associated with poor prognosis (HR 1.36 95% CI 1.12-1.66, p=0.006, Figure 1C), with 
patients with one high or both high having similar prognosis. No associations were seen for 
the cytoplasmic FGR+HCK score and CSS. 
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To assess the effects on lymphocytic infiltrate, associations with clinicopathological factors 
and inflammation were assessed as shown in Table 4. A both high membrane FGR+HCK 
score significantly associated with younger age (p=0.012), rectal cancer (p=0.039), higher 
TNM-stage (p=0.004), lower proliferation rate (p<0.001), decrease T-lymphocytes (p=0.020), 
cytotoxic T-lymphocytes (p<0.001) and PD1-TILs (p=0.045). Whereas a high cytoplasmic 
FGR+HCK score only associated with increased proliferation rate (p=0.007) and increased 
PD-L1 TILs (p=0.003). 
 
Membrane FGR+HCK Cytoplasmic FGR + HCK 
Both Low One Low Both High P Both Low One High Both High P 
(n=335) (n=402) (n=78)   (n=136) (n=408) (n=225)   
Age 
   
0.012 
   
0.632 
<65 95 (28) 134 (33) 33 (42)   51 (37) 117 (28) 75 (33) 
 
>65 245 (72) 270 (67) 45 (58)   86 (63) 295 (72) 152 (67) 
 Sex 
   
0.871 
   
0.373 
Female 156 (46) 185 (46) 37 (47)   60 (44) 189 (46) 110 (49) 
 Male 184 (54) 219 (54) 41 (53)   77 (56) 224 (54) 117 (51) 
 Tumour site 
   
0.039 
   
0.249 
Colon  261 (77) 308 (76) 48 (62) 
  
94 (69) 318 (77) 171 (75) 
 Rectum 79 (23) 96 (24) 30 (38) 
  
43 (31) 94 (22) 56 (25) 
 TNM-stage 
   
0.004 
   
0.056 
I 58 (17) 50 (12) 6 (8)   22 (16) 58 (14) 23 (10) 
 II 163 (48) 201 (50) 32 (41)   70 (51) 199 (48) 112 (49) 
 III 119 (35) 153 (38) 50 (51)   45 (33) 155 (38) 92 (41) 
 Differentiation 
   
0.143 
   
0.340 
Mod/well 316 (93) 357 (88) 71 (91)   125 (91) 375 (91) 201 (89) 
 Poor 24 (7) 47 (12) 7 (9)   12 (9) 37 (9) 26 (11) 
 Venous invasion 
   
0.454 
   
0.605 
Absent 235 (69) 267 (66) 52 (67)   95 (69) 266 (65) 160 (70) 
 Present 105 (31) 137 (34) 26 (33)   42 (31) 146 (35) 67 (30) 
 Margin involvement 
   
0.592 
   
0.070 
No 321 (94) 381 (94) 72 (92)   132 (96) 391 (95) 209 (92) 
 Yes 19 (6) 23 (6) 6 (8)   5 (4) 21 (5) 18 (8) 
 Peritoneal involvement 
   
0.910 
   
0.130 
No 249 (73) 291 (72) 59 (76)   95 (69) 295 (72) 173 (76) 
 Yes 91 (27) 113 (28) 19 (24)   42 (31) 117 (28) 54 (24) 
 Mismatch repair status   
   
0.753 
   
0.133 
Competent 284 (84) 333 (83) 64 (83)   109 (80) 337 (82) 195 (86) 
 Deficient 55 (16) 70 (17) 13 (17)   27 (20) 74 (18) 32 (14) 
 Proliferation Index 
   
<0.001 
   
0.007 
Low 141 (42) 180 (43) 56 (72)   75 (56) 184 (45) 91 (40) 
 High 199 (58) 220 (55) 22 (28)   60 (44) 227 (55) 135 (60) 
 Necrosis  
   
0.094 
   
0.535 
Low 189 (57) 253 (64) 48 (62)   88 (65) 237 (59) 135 (61) 
 High 144 (43) 142 (36) 29 (38)   47 (35) 166 (41) 87 (39) 
 Tumour stroma percentage 
   
0.056 
   
0.809 
Low 269 (79) 291 (75) 51 (70)   94 (73) 317 (79) 163 (73) 
 High 70 (21) 96 (25) 22 (30)   35 (27) 85 (21) 59 (27) 
 Klintrup-Makinen grade 
   
0.599 
   
0.646 
Weak 228 (69) 260 (66) 52 (68)   92 (68) 263 (65) 155 (70) 
 Strong 105 (31) 136 (34) 25 (32)   43 (32) 140 (35) 68 (30) 
 CD3+ Lymphocytes 
   
0.020 
   
0.187 
Low 91 (30) 143 (38) 32 (42)   50 (29) 142 (38) 65 (30) 
 Moderate 99 (32) 106 (29) 22 (28)   35 (27) 108 (29) 70 (33) 
 High 115 (38) 123 (33) 23 (30)   44 (34) 125 (33) 78 (37) 
 CD8+ Lymphocytes 
   
<0.001 
   
0.615 
Low 121 (41) 177 (48) 45 (61)   67 (54) 163 (44) 104 (50) 
 Moderate 79 (26) 100 (27) 20 (27)   28 (22) 105 (28) 47 (22) 
 High 99 (33) 93 (25) 9 (12)   30 (24) 106 (28) 58 (28) 
 FoxP3+ Lymphocytes 
   
0.513 
   
0.051 
Low 72 (29) 116 (35) 30 (41)   47 (42) 107 (32) 51 (28) 
 Moderate 101 (40) 124 (38) 12 (16)   36 (32) 121 (36) 74 (41) 
 High 77 (31) 88 (27) 32 (43)   29 (26) 106 (32) 58 (32) 
 PD1 – TILs 
   
0.045 
   
0.327 
Low 171 (65) 227 (68) 55 (79)   80 (72) 224 (66) 125 (66) 
 High 94 (35) 109 (32) 15 (21)   31 (28) 116 (34) 65 (34) 
 PD-L1 – TILs 
   
0.567 
   
0.033 
Low 199 (75) 250 (75) 59 (79)   94 (81) 254 (76) 135 (70) 
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High 67 (25) 82 (25) 16 (21)   22 (19) 82 (24) 57 (30) 
 PD-L1 – tumour 
   
0.084 
   
0.263 
Low 150 (57) 187 (55) 33 (44)   58 (50) 196 (58) 90 (45) 
 High 113 (43) 154 (45) 42 (56)   59 (50) 142 (42) 106 (55) 
 
mGPS 
   
0.633 
   
0.190 
0 158 (59) 164 (52) 48 (62)   62 (53) 173 (54) 116 (61) 
 1 73 (27) 84 (26) 25 (32)   35 (30) 90 (28) 46 (24) 
 2 35 (13) 70 (22) 5 (6)   19 (17) 57 (18) 27 (14) 
 NLR 
   
0.247 
   
0.987 
<5 213 (76) 223 (68) 50 (75)   82 (73) 243 (72) 134 (73) 
 
>5 68 (24) 103 (32) 17 (25)   30 (27) 95 (28) 50 (27)   
Table 4. Relationship between combined FGR+HCK expression and clinicopathological characteristics in 
patients undergoing potentially curative resection of colorectal cancer (n=822). 
Cytoplasmic HCK is an independent prognostic factor for patients with CRC 
FGR, HCK and the combined score were then taken into cox regression multivariate analysis 
along with significant clinical, pathological and inflammatory markers as shown in Table 5. 
On multivariate analysis (n=406), TMN-stage (p<0.001), venous invasion (p=0.012), margin 
involvement (p=0.030), peritoneal involvement (p=0.001), KM grade (p=0.015), T-
lymphocytes (p=0.012), mGPS (p<0.001) and cytoplasmic HCK (p=0.015) were independent 
prognostic factors.  However, membrane FGR (P=0.590), membrane HCK (P=0.287) and the 
combined membrane FGR+HCK score (p=0.167) were not independently associated with 
CCS. 
 n=822 n=406 
 Univariate HR P Multivariate HR P 
(95% CI) 
  
(95% CI) 
  
Clinicopathological Characteristics 
Age (<65/>65) 1.03 (0.78-1.35) 0.854 - - 
Sex (Female/Male) 1.12 (0.87-1.46) 0.386 - - 
Tumour Site (Colon/Rectum) 0.96 (0.71-1.29) 0.809 - - 
TNM-Stage (I/II/III) 2.41 (1.94-3.01) <0.001 1.87 (1.33-2.64) <0.001 
Differentiation (Moderate or well/Poor) 1.97 (1.35-2.86) <0.001 0.99 (0.58-1.70) 0.750 
Venous Invasion (Absent/Present) 2.16 (1.67-2.80) <0.001 1.62 (1.11-2.38) 0.012 
Margin Involvement (No/Yes) 3.27 (2.18-4.88) <0.001 1.87 (1.06-3.28) 0.030 
Peritoneal Involvement (No/Yes) 2.76 (2.25-3.57) <0.001 1.94 (1.33-2.83) 0.001 
Mismatch Repair Status (Competent/Deficient) 0.77 (0.53-1.12) 0.168 - - 
Ki67 Proliferation (Low/high) 0.65 (0.50-0.85) b 0.99 (0.67-1.47) 0.704 
Necrosis (Low/High) 1.32 (1.02-1.72) 0.038 1.20 (0.85-1.70) 0.180 
Tumour Stroma Percentage (<50%/>50%) 1.81 (1.37-2.38) <0.001 1.42 (0.99-2.05) 0.227 
Inflammatory Characteristics 
Klintrup-Makinen Grade (Weak/Strong) 0.38 (0.27-0.54) <0.001 0.54 (0.33-0.89) 0.015 
CD3+ Lymphocytes (low/moderate/high) 0.67 (0.56-0.79) <0.001 0.75 (0.59-0.90) 0.012 
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CD8+ Lymphocytes (low/moderate/high) 0.63 (0.53-0.75) <0.001 0.92 (0.71-1.19) 0.566 
FoxP3+ Lymphocytes (low/moderate/high) 0.68 (0.56-0.82) <0.001 1.03 (0.80-1.33) 0.942 
PD1 – TILs (low/high) 0.55 (0.39-0.77) 0.001 0.71 (0.45-1.11) 0.211 
PD-L1 – TILs (low/high) 0.86 (0.61-1.21) 0.392 - - 
PD-L1 – tumour (low/high) 1.08 (0.82-1.44) 0.559 - - 
mGPS (0/1/2) 1.74 (1.46-2.07) <0.001 1.62 (1.27-2.07) <0.001 
NLR (<5/>5) 1.44 (1.06-1.96) 0.018 1.26 (0.87-1.82) 0.620 
SFKs 
Membrane FGR (absent/present) 1.38 (1.06-1.80) 0.017 1.14 (0.80-1.64) 0.590 
Membrane HCK (low/high) 1.48 (1.06-2.06) 0.020 1.38 (0.83-2.31) 0.287 
Cytoplasmic HCK (low/high) 1.34 (1.03-1.75) 0.031 1.58 (1.09-2.07) 0.015 
Membrane FGR+HCK (both low/one high/both high) 1.36 (1.12-1.66) 0.002 1.20 (0.93-1.57) 0.167 
Table 5.   Clinicopathological characteristics of patients undergoing elective, potentially curative resection 
of colorectal cancer and survival 
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DISCUSSION 
The results of this study provide evidence that FGR and HCK are highly expressed in CRC 
tumours and are associated with poorer patient prognosis. FGR and HCK are important 
within both the tumour, were they associated with increased TNM-stage and decreased 
proliferation, and within the microenvironment, were they showed strong associations with 
decreased local inflammation and PD1/PD-L1 expression on lymphocytes. Therefore, HCK 
and FGR may work synergistically to promote tumour progression and dampen the local 
lymphocytic inflammatory infiltrate. 
The results within the present study are consistent with other studies that have suggested that 
HCK is overexpressed in CRC and correlates with poor patient prognosis.  This poor 
prognosis is suggested to be due to effects on proliferation and facilitation of an alternative 
M2-like macrophage polarisation15, 31.  This is similar to the results seen in the present study, 
HCK associates with decreased proliferation and poorer differentiation suggesting HCK 
overexpression promotes tumourigenesis. HCK has also been associated with tumour 
progression in other malignancies. In Chronic Myeloid leukaemia (CLL) increased 
expression of HCK associated with increased cell survival.  This increase was due to direct 
interactions of HCK with BCR/ABL and STAT5 to up-regulate the Akt pathway, which is 
also known to regulate inflammation15.  However, in renal cancer, active membrane HCK 
associated with increased CSS, in contrast to the results seen in the present study, suggesting 
the tumour origin and microenvironment may be important18. Previous literature on FGR in 
colorectal cancer is lacking, the current study suggests that FGR may be a tumour promoter 
that works by dampening T-lymphocyte infiltration in to the tumour and microenvironment.  
The data further suggests that FGR and HCK work in synergy as when assessed together as 
part of a combined membrane score, a both high score and one high score show similar 
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prognostic value, suggesting that they both work independently towards the same goal rather 
than together. 
HCK and FGR also play an important role in the innate immune response via modulation of 
neutrophil phagocytosis, macrophage proliferation and migration32-34.  However, HCK and 
FGR mainly exploit the innate immune response through regulating of the production of 
cytokines.  When HCK and FGR are knocked out in mice in conjunction with LYN, the mice 
are completely protected from inflammatory effects due to defects in cytokine production, 
suggesting they work together35. HCK can also promote IL-6 secretion to up-regulate 
adaptive inflammation, yet HCK is likewise activated by IL-6 via direct interactions with 
GP130 to promote cell proliferation15. However, HCK has also been shown to be a negative 
regulator of neutrophil chemokine signalling to dampen local inflammatory responses36.  This 
may be the case in the present study, when FGR and/or HCK are activated, they can then 
work in synergy to negatively regulate important cytokines, ordinarily secreted by neutrophils 
for T-lymphocyte recruitment within the tumour, which may explain why T-lymphocyte 
numbers decrease in our patients.  However, another explanation may be that HCK and FGRs 
aberrant activation of innate immune cells in the tumour microenvironment facilitates 
tumourigenesis and enables progression in CRC. In a small subset of 100 patients from the  
study, membrane FGR but not HCK significantly shifted macrophage polarisation towards an 
M2-like phenotype, which has been shown to promote tumourigenesis and dampen 
lymphocytic inflitration (data not shown). Furthermore, this was supported by the results of 
the combined membrane score, were a both high score showed a greater effect on cytotoxic 
T-lymphocyte infiltration than a one high or both low score. This suggest although they can 
both work independently to regulate tumour progression and local inflammation, this effect is 
increased when acting synergistically towards a common goal. 
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In conclusion, the results of this study support HCK and FGR as active SFKs in patients with 
CRC that act in synergy to promote tumour progression and dampen local lymphocytic 
inflammation. Therefore, these two SFKs may help predict the prognosis of patients with 
CRC if incorporated into routine pathology alongside TNM-staging. They may also provide a 
therapeutic target and biomarker, with clinical inhibitors available, that may show value if 
targeted in clinical trials in conjunction with current immunotherapies in patients with high 
membrane expression.  
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